Role of Circulating Pyrophosphate as a Biomarker of Mediacalcinosis in Type 2 Diabetic Patients

Inclusion criteria

• Adult men (between 40 and 70 years of age).
• T2DM defined according to ADA or HAS criteria, evolving for more than 6 months, may be : - Not complicated

• Complicated by diabetic retinopathy and/or diabetic nephropathy (creatinine clearance > 60 ml/min) and/or peripheral arterial disease and/or ischemic heart disease and/or stroke. - With dyslipidemia (LDLc > 1.90) and/or a history of past or active smoking.
• Balanced with HbA1c < 8% according to patient's personalized objectives, or unbalanced with HbA1c > 9%.
• Treated with insulin therapy (single or multi-injections) or not. - Whose treatment includes at least one iSGLT2.
• Member of 'Sécurité Sociale"

Exclusion criteria

• Patient already included in another study.
• Patient in a particular situation judged incompatible with the study by the investigator.
• Patient living in a department other than Alpes-Maritimes or Var.
• Patient refusing to give consent.
• Patient deprived of liberty by administrative or judicial decision, under guardianship or curatorship.
• Patient with decompensated hepatic cirrhosis (Child C and above, score 10 to 15 points).
• Patients with chronic kidney disease (from stage 3, i.e. GFR < 59 ml/min/1.73 m2).
• Patient with a recent fracture (within the last 3 months).
• Patient treated with AVK or biphosphonates.
• Patient with known, treated osteoporosis.
• Patient with unsupplemented vitamin D deficiency.
• Patient with active cancer.
• Patient with an active inflammatory pathology.